A sticky situation: New insight into manufacturing safer biopharmaceuticals at lower cost
Wednesday, January 20, 2016 - 09:21
in Health & Medicine
Monoclonal antibodies are an important new class of drugs to treat cancer, heart disease and a range of other conditions. However, their production in mammalian cells introduces a large number of contaminants that are difficult to remove during purification. Now, by looking at how antibodies change chemically during purification, A*STAR scientists have identified a better way to eliminate contaminants.